What is the current stock price of Bioventus Inc. (BVS)?

As of the latest market data, Bioventus Inc. (BVS) is trading at $8.90. The stock has seen a loss of -1.33% today.

Does Bioventus Inc. (BVS) pay a dividend?

Based on current data, Bioventus Inc. does not have a confirmed active dividend policy.

What is the market cap of Bioventus Inc.?

The current market capitalization of Bioventus Inc. (BVS) is approximately unavailable.

BVS

Bioventus Inc.·Healthcare

8.90

1.330%(−0.12)

Close Price

9.50

6.742%(+0.60)

Pre-Market

Last Updated: — ET

52W L: $5.8152W H: $11.25

BVS NEWS

zacks.com

6d ago

Is Bioventus (BVS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com

May 18

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.

247wallst.com

May 14

Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next

Consumer confidence is breaking down in a way investors have not seen in years. The University of Michigan Consumer Sentiment Index landed at 53.3 in March 2026, sitting below the 60 recessionary threshold, and the latest Surveys of Consumers reading dropped further to 49.8 in April 2026, a 6.6% month-over-month decline matching the trough from June 2022.

zacks.com

May 8

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

seekingalpha.com

May 6

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

zacks.com

May 6

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.

Company Profile

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Sector

Healthcare

Industry

Medical - Devices

Employees

930

IPO Date

2021-02-11

Beta

0.72

Websitewww.bioventus.com↗